Pausing for Halftime: A Stratified Analysis of Epidemiological Characteristics and Outcomes in CMV-Seropositive Allogeneic HSCT Recipients with Cscmvi before and after Day 100 (TCT-ASTCT-CIBMTR 2026) - Jan 8, 2026 - Abstract #782; 589; Pres time: Feb 5, 2026; 06:30 PM - 08:00 PM; Location: Hall AB (Salt Palace Convention Center); "Most patients were treated with Valganciclovir (90%). Prospective studies are needed to evaluate safety, efficacy, and mortality benefits of prolonged prophylaxis in high-risk subgroups. -Descriptive analysis comparing epidemiological characteristics between CMV-seropositive recipients of allo-HSCT patients transplanted at the Cleveland Clinic who developed early vs late csCMVi following primary Letermovir prophyaxis -Identification of potential risk factors for delayed csCMVi that may potentially inform decisions around extending CMV prophylaxis beyond day 100 post-transplant -Stratified comparison of various outcomes, including incidence of invasive disease, recurrent disease, hematological disease relapse, all-cause mortality, time to mortality from csCMVi/ transplant"
Clinical • Bone Marrow Transplantation • Cytomegalovirus Infection • Graft versus Host Disease • Hematological Disorders • Immunology • Infectious Disease
|
|
Safah Khan; Kristina Nasr; Mohammed Akbar; Zachary Yetmar
|